New Delhi: Drug major Dr Reddy's Laboratories on Thursday announced a royalty-free, non-exclusive voluntary licensing agreement with Gilead Sciences for investigational once-yearly lenacapavir used as pre-exposure prophylaxis (PrEP) for HIV prevention.
The agreement aims to facilitate manufacturing readiness, technology transfer, and future supply planning across 120 high-incidence licensed countries, including India, primarily low- and lower-middle-income nations, the company said in a release.
